The Telltales Investor (episode 2410)

[00:00:00] IntroMike set the stage for an episode packed with energy, tech, biotech analysis and a special guest from the OakCliff Sailing Center.[00:01:14] Exhibit C: World Oil Supply/DemandHunt discussed Saudi Arabia's potential to unleash 3 million barrels per day of held-back oil production to flex on cheating OPEC nations. A simple move with profound market implications.[00:01:58] Exhibit B: US Gas Demand/Supply Warm weather had depressed natural gas prices lately. But the team saw prices firming if production is curtailed. [00:03:06] Exhibit A: US Gov't Revenues and ExpensesProgress inched forward on the U.S. budget process. The government machine lurched onward. [00:03:38] Page 1: AAPL/AMZN/GOOG/MSFT/TSLADissecting tech titan free cash flows revealed insights: Amazon's logistics build-out, Google's bloated hiring, Tesla's software potential. Following the money trail leads to understanding.[00:13:23] Oakcliff Sailing Update Dawn Riley inspired with tales of Oakcliff alumni sailing victories worldwide. The lure of the open water summons all.[00:14:57] Investing in Healthcare & BiotechMike and Jason outlined their approach to biotech at Top Mark Capital: growing free cash flows, moats, innovating in stagnant sectors, funding R&D internally. A straightforward but potent strategy for asymmetric returns.[00:16:43] Page 15: PFE/MRNA/LNTH/BNTX/VRTXVertex exemplified the ideal - spending half its cash flow on R&D for a new non-opioid pain drug, its cystic fibrosis franchise providing a strong moat.[00:21:02] Page 19: UNH/CVS/REGN/BIIB/LLY Larger biotechs like Lilly were assessed, but smaller innovators offered more potential upside per the team's criteria. Risk and opportunity in equilibrium.[00:23:10] What is RNA?Jason eloquently explained RNA technology's role in COVID vaccines and vast future cancer treatment potential. Knowledge is indispensable.This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com